Omeros | OMER - Operating Expenses


Omeros reported $59.16M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Adma Biologics USD 71.95M 7.75M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Cytokinetics USD 214.64M 6.85M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
MacroGenics USD 42.87M 21.68M Jun/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 1.18B 995.96M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Rockwell Medical USD 30.41M 1.11M Jun/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026